Introduction
============

Syphilis has been a major cause of mortality and morbidity for around 500 years ([@B1]). The World Health Organization (WHO) estimates that 12 million new cases of syphilis occur each year ([@B50], [@B51]). In Chinese history, syphilis had been eradicated over a period in 1960s, but by the late 1990s, China's reported syphilis cases were rising by about 30% per year ([@B4]). The reported incidence of syphilis more than tripled between 2005 and 2011, to 32.0 cases per 100 000 people. This increasing trend was continuously observed in 2012 ([@B5], [@B6]). Facing the continually increasing epidemic of syphilis in China, the government has recognized that enhanced efforts are needed to respond to the epidemic. Specifically, in 2010, the China's Ministry of Health (MOH) officially launched the first national program specially and directly aimed at controlling syphilis: the National Program for Prevention and Control of Syphilis in China (2010--2020)([@B7]). However, the spread of syphilis transmission seem not to be prevented actually. Worriedly, a new problem of the persistent positive serological reaction after treatment among syphilitic patients is coming with the spread of syphilis, which is bound to bring about new difficulties for prevention of syphilis transmission.

Syphilis management requires serological monitoring after therapy ([@B8]--[@B12]). "Not all patients achieve serological reversal after the recommended treatment; some patients demonstrate a persistent positive serological reaction that was quite disconcerting for both the physician and patient" ([@B13]). It remains unclear whether the persistent positive serological reaction indicates persistent foci of spirochetes or progressive syphilitic lesions or whether it reflects the persistence of regain in the circulating blood following anti-syphilitic therapy. For these reasons, a discussion about the serological response after the recommended therapy is more than justified. In China, in a substantial proportion(10.0% for primary syphilis, 17.5% for secondary syphilis, and 40.5% for latent syphilis) of patients with syphilis, nontreponemal titers neither increase nor decrease 4-fold after treatment and are referred to as being "serofast"([@B14]--[@B18]). Until now, the factors that predict the serological response after the recommended therapy among syphilitic patients have not yet been thoroughly studied. A clear understanding of predictors is important to define interventions in every community. With recently accumulating evidence, our goal, therefore, was to summarize factors associated with serofast state of HIV-negative patients with syphilis in China by conducting a meta-analysis of published studies, which serves to guide clinicians regarding the identification of patients who may become serofast after therapy without clear evidence of treatment failure, and develop the optimal management program of serofast patients.

Methods
=======

Literature search
-----------------

We attempted to report this meta-analysis in accordance with the Meta-Analysis of Observational Studies in Epidemiology guidelines ([@B19]). We used and combined the following keywords: "(Serofast OR Seroresistance OR Serum fixed OR Serological cure OR Serological response) AND Syphilis AND China". We searched both international and national electronic databases as follows: PubMed (January 1950 to September 2013), Google Scholar (January 1950 to September 2013), Chinese National Knowledge Infrastructure (CNKI) (January 1994 to September 2013), Chinese Scientific Journals Fulltext Database (CQVIP)(January 1989 to September 2013), China Biology Medicine disc(CBMdisc)(January 1978 to September 2013), and Wanfang Data(January 1998 to September 2013). We also scanned the reference lists of all included studies for additional references. The grey literatures and conference abstracts were not searched. When reported data were not sufficient for estimation of desired comparisons, we contacted study authors.

Selection criteria
------------------

We first performed an initial screening of titles or abstracts. A second screening was based on full-text review. Studies were considered eligible for inclusion if they met the following criteria: 1) the study assessed the risk factors of serofast; 2) the study was published in Chinese or English language; 3) study participants were Chinese populations with syphilis but without HIV infection; 4) definition of serofast was clear; 5) all syphilitic patients received recommended therapy according to CDC guidelines([@B8]) before diagnosed as serofast; 6) the exposure of interest was clinical characteristics, the levels of T-lymphocyte subset and NK cells in the peripheral blood, and the levels of interleukin and interferon in the serum; 7) the outcome of interest was serofast; 8) corresponding data were provided; 9) the study design was a cohort or case-control study. We excluded review papers, non-peer-reviewed local/government reports, conference abstract and presentation in the present study. Multiple papers from the same center and/or authors were analyzed to determine whether the most recent publication was an accumulation, which included cases, reported in earlier publications. If this was evident from our review, then we used only the most recent publication. We also assessed potential studies to ensure that there was no duplication of case series.

Group definitions and measure of exposure
-----------------------------------------

After recommended therapy (non--penicillin-allergic participants were given 3 injections of 2.4 million units of benzathine penicillin at weekly intervals; penicillin-allergic participants were given doxycycline or azithromycin or erythromycin), syphilis patients were considered to be in a serofast state if their nontreponemal antibodies test remained positive and the titres neither increased nor decreased by at least four-fold (two dilutions)([@B9], [@B10]). Syphilis patients whose clinical manifestations disappeared and whose nontreponemal antibodies titers became negative or decreased by four-fold(two dilutions) were regarded as achieving a serological cure([@B9], [@B10]). Health group consisted of populations who went to the hospital to donate blood or seek a physical examination. They were not infected with syphilis and HIV. The Flow cytometry was used to detect the levels of T-lymphocyte subset and NK cells in the peripheral blood among health group, serofast group and serological cure group. The Enzyme linked immunosorbent assay (ELISA) was also used to detect the levels of Interleukin and interferon in the serum among healthy group, serofast group and serological cure group.

Data extraction and quality assessment
--------------------------------------

Two independent reviewers (QJB and YTB) extracted data and assessed study quality. Any disagreements were resolved through discussion among the authors until consensus was reached. Data extraction was then performed using a standardized data-collection form. For cohort studies, the following data were extracted: first author and year of publication; study location; study design/period; duration of follow-up; study population; exposure and outcome; methods of data collection; and comment. For case-control studies, the following data were extracted: first author and year of publication; study location; study design/period; case group/sample size; control group/sample size; exposure; measure of exposure; and comment.

We adapted the principles of the Newcastle-Ottawa-Scale (NOS) to assess the risk of bias in the included studies ([@B20]). In statistics, the scale is a tool used for assessing the quality of non-randomized studies included in a systematic review and/or meta-analysis. Using the tool, each study is judged on eight items, categorized into three groups: the selection of the study groups; the comparability of the groups; and the ascertainment of outcome or exposure. Stars awarded for each quality item serve as a quick visual assessment. Stars are awarded such that the highest quality studies are awarded up to nine stars. When the study gains at least six stars, it is considered of low-risk of bias ([@B21]). We only included studies with low-risk of bias.

Statistical analysis
--------------------

The summary risk ratio (sRR) and standardized mean difference (SMD), respectively, were used for qualitative data and quantitative data to measure of the association between serofast and its potential risk factors, and odd ratios and incidence rate ratios were directly considered as RRs. Homogeneity of effect size across studies was tested by using the Q statistics at the *P*\<0.10 level of significance. The I^2^ statistic, which is a quantitative measure of inconsistency across studies, was also calculated (significance level at I^2^\>50%) ([@B22]). sRR or SMD and their corresponding 95%CI were calculated using either fixed-effects models or, in the presence of heterogeneity, random-effects models ([@B23]). Sensitivity analysis was conducted to explore possible explanations for heterogeneity and examine the influence of various exclusion criteria on the overall risk estimate. We also investigated the influence of a single study on the overall risk estimate by omitting one study in each turn. Potential publication bias was assessed by visual inspection of the Begg's funnel plots, Begg's rank correlation test, Egger's linear regression test, and Macaskill's test ([@B24]). Begg's rank correlation test, Egger's linear regression test, and Macaskill's test were performed by using SAS version 8.2(SAS Institute, Cary, NC, USA). Other analyses were performed by Review Manager-version 5.0. A *P* value \<0.05 was considered statistically significant, except where otherwise specified.

Results
=======

Study selection and study quality assessment
--------------------------------------------

Overall, 1245 studies were identified, of which 402 potentially relevant articles were selected for further screening, and eventually 27 studies ([@B10],[@B11],[@B14],[@B17],[@B18],[@B25]--[@B46]) involving 6682 HIV-negative participants with Syphilis in China were considered eligible for inclusion ([Fig.1](#F1){ref-type="fig"}). The extracted data involving 11 cohort studies and 16 case-control studies and published between 2005 and 2013 were shown in [Table 1](#T1){ref-type="table"}. The shortest length from first treatment to diagnosis of serofast after treatment was more than 6 months, and the length in 92.6 %( 25/27) of eligible studies was ≥ one year. In all studies, blood sample were tested for HIV and syphilis. Some studies comprising participants with positive HIV test have been excluded. In included studies, participants with serum positive for both *Treponema pallidum* particle assay(TPPA) and rapid plasma regain(RPR) or toluidine red unheated serum test(TRUST) were determined to be currently infected with syphilis. RPR or TRUST titers were used to evaluate serological response at 6 and 12 months after treatment for primary and secondary syphilis and, additionally, at 24 months for latent syphilis.

![Study identification flowchart](ijph-44-155f1){#F1}

###### 

Characteristics of 27 included studies

  **Reference number**   **Location**   **Study design/period**           **Duration of follow-up**   **Study population**   **Exposure**                                                                               **Outcomes**                           **Methods of data collection**                       **Comment**
  ---------------------- -------------- --------------------------------- --------------------------- ---------------------- ------------------------------------------------------------------------------------------ -------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **17**                 Guangzhou      Retrospective cohort/1994--2003   2 years                     423 patients           Age, gender, stage of syphilis and initial titers of non-treponema antibodies              Serofast status and serological cure   Medical records                                      In this study, the clinical data of patients with syphilis in the recent ten years were reviewed, the incidence and the duration of occurrence of serofast, the relationship between serofast and age, sex, stage of disease, RPR initial titer of the patients were analyzed respectively by multiple regression
  **18**                 Beijing        Retrospective cohort/2001--2005   2 years                     131 patients           Age, gender, initial titers of non-treponema antibodies, stage of syphilis and treatment   Serofast status and serological cure   Medical records                                      In this study, the incidence of serofast was investigated and the correlation between serofast and factors including age, gender, initial titer, disease course, and medications were analyzed.
  **25**                 Zhangzhou      Retrospective cohort/2002--2006   2 years                     224 patients           Stage of syphilis                                                                          Serofast status and serological cure   Medical records                                      In this study, based on 5 years clinical data, the incidence of serofast was investigated and the correlation between serofast and stage of syphilis was analyzed.
  **26**                 Liuzhou        Retrospective cohort/2002--2006   2 years                     318 patients           Stage of syphilis                                                                          Serofast status and serological cure   Medical records                                      In this study, the incidences of serofast based on stage of syphilis and the time when serofast were formed were analyzed.
  **27**                 Beijing        Retrospective cohort/unknown      Unknown                     172 patients           Stage of syphilis, treatment, T-lymphocyte subset and NK cells in the peripheral blood     Serofast status and serological cure   Medical records and Flow cytometry                   In this study, the correlation between serofast and related factors including initial titer of RPR, disease course, and medication. Flow cytometry was used to analyze T-lymphocyte subset and NK cells in the peripheral blood of untreated syphilitic patients, syphilitic patients whose serology turned negative after treatment, serofast patients, and healthy controls.
  **28**                 Guangzhou      Retrospective cohort/2005--2009   \>2 years                   366 patients           Stage of syphilis and treatment                                                            Serofast status and serological cure   Medical records                                      In this study, the incidences of serofast based on stage of syphilis, treatment factors, and the time when serofast were formed were analyzed.
  **29**                 Guangzhou      Prospective cohort/2008--2009     1 years                     102 patients           Subtypes of *Treponema pallidum* repeat(tpr) gene                                          Serofast status and serological cure   Medical records and Polymerase Chain Reaction(PCR)   In this study, specimens of confirmed patients with untreated early syphilis were collected by multiple centers cooperation. *Treponema pallidum* basic membrane protein (bmp) genes were screened from these specimens by nested PCR. After standard treatment, the relationship between the change of serum TRUST titer of the patients and the subtypes of tpr gene were analyzed.
  **30**                 Shanghai       Prospective cohort/2002--2009     \>2years                    420 patients           Stage of syphilis                                                                          Serofast status and serological cure   Medical records                                      In this study, the incidences of serofast based on stage of syphilis and the association between serofast and stage of syphilis were analyzed.
  **14**                 Xiamen         Prospective cohort/2005--2009     1 year                      1308 patients          Stage of syphilis and treponema pallidum(TP) IgM antibody                                  Serofast status and serological cure   Medical records                                      In this study, TP-IgM was detected with FTA-Abs and TPPA. Syphilis patients were divided into experimental groups according to the results of TRUST and TPPA. Relationship between serofast, stage of syphilis, and TP-IgM were analyzed.
  **11**                 Beijing        Prospective cohort/2000--2010     \>6 months                  501 patients           Demographic characteristics, clinical characteristics, and behavior characteristics        Serofast status and serological cure   Medical records                                      In this study, analysis of factors determining the serological response to treatment was performed in HIV-negative patients with early syphilis, using demographic characteristics, clinical characteristics, and behavior characteristics
  **10**                 Xiamen         Prospective cohort/2005--2010     1 year                      1327 patients          Age, gender, initial titers of non-treponema antibodies, and stage of syphilis             Serofast status and serological cure   Medical records                                      In this study, the incidence of serofast was investigated and the correlation between serofast and factors including age, gender, initial titer, and disease course were analyzed.

Abbreviation: PCR= polymerase chain reaction; FTA-Abs= fluorescent treponemal antibody absorption; TPPA= Treponema pallidum particle agglutination; TP= Treponema Pallidum

  **Reference number**   **Location**                                 **Study design/period**   **Case group/sample size**    **Control group/ sample size**                       **Exposure**                                                                                      **Measure of exposure**    **Comment**
  ---------------------- -------------------------------------------- ------------------------- ----------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  31                     Guangzhou                                    HCC/unknown               **Serofast group/32 cases**   Healthy group/30 cases                               T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood between serofast group and healthy group were compared.
  32                     Guangzhou                                    HCC/unknown               Serofast group/38 cases       Healthy group/23 cases                               T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood between serofast group and healthy group were compared.
  33                     Shenzhen                                     HCC/unknown               Serofast group/30 cases       Healthy group/30 cases                               T-lymphocyte subset                                                                               Flow cytometry             In this study, the levels of T-lymphocyte subset in the peripheral blood between serofast group and healthy group were compared.
  34                     Nanchang                                     HCC/2004--2006            Serofast group/20 cases       Healthy group/20 cases; Serological cure/20 cases    The levels of IFN-r and IL-10 in the serum                                                        ELISA                      In this study, the levels of IFN-r and IL-10 in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared, respectively.
  35                     Guangzhou                                    HCC/2001--2006            Serofast group/58 cases       Serological cure/60 cases                            T-lymphocyte subset in the peripheral blood                                                       Flow cytometry             In this study, the levels of T-lymphocyte subset in the peripheral blood between serofast patients and syphilitic patients whose serology turned negative after treatment were compared.
  36                     2 cities [^a^](#TFN3){ref-type="table-fn"}   HCC/2003--2006            Serofast group/38 cases       Healthy group/23 cases                               The levels of IL-12 and IL-10 in the serum                                                        ELISA                      In this study, the levels of IL-12 and IL-10 in the serum of serofast patients and healthy group were compared.
  37                     Chengdu                                      HCC/2005--2007            Serofast group/20 cases       Healthy group/30 cases; Serological cure/30 cases    T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared.
  38                     Chongqing                                    HCC/2004--2006            Serofast group/20 cases       Healthy group/30 cases; Serological cure/20 cases    The levels of IL-2 and IL-10 in the serum                                                         ELISA                      In this study, the levels of IL-2 and IL-10 in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared, respectively.
  39                     Suzhou                                       HCC/2008--2009            Serofast group/23 cases       Healthy group/20 cases; Serological cure/20 cases    T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared.
  40                     Hefei                                        HCC/2005--2009            Serofast group/25 cases       Healthy group/20 cases;                              T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients and healthy controls were compared.
  41                     Dongguan                                     HCC/2009--2010            Serofast group/18 cases       Healthy group/18 cases;                              CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-17 in the serum                   Flow cytometry and ELISA   In this study, the levels of CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-17 in the serum of serofast patients, and healthy controls were compared.
  42                     Shenzhen                                     HCC/2010--2011            Serofast group/60 cases       Healthy group/63 cases; Serological cure/61 cases    T-lymphocyte subset in the peripheral blood, and IL-17 and IL-23 in the serum                     Flow cytometry and ELISA   In this study, the levels of T-lymphocyte subset in the peripheral blood, and IL-17 and IL-23 in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared.
  43                     Jieyang                                      HCC/unknown               Serofast group/112 cases      Healthy group/58 cases; Serological cure/155 cases   CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-10, IL-6 and IFN-r in the serum   Flow cytometry and ELISA   In this study, the levels of CD4(+)CD25(+) regulatory T cells in the peripheral blood and IL-0, IL-6 and IFN-r in the serum of serofast patients, syphilitic patients whose serology turned negative after treatment, and healthy controls were compared.
  44                     Nanning                                      HCC/2007--2011            Serofast group/32 cases       Healthy group/22 cases                               The levels of IL-2, IL-4, IL-10, and IL-12 in the serum                                           ELISA                      In this study, the levels of IL-2, IL-4, IL-10, and IL-12 in the serum of serofast patients, and healthy controls were compared.
  45                     Nanning                                      HCC/2007--2011            Serofast group/32 cases       Healthy group/11 cases                               T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, and healthy controls were compared.
  46                     Hanchuan                                     HCC/2007--2011            Serofast group/46 cases       Healthy group/22 cases                               T-lymphocyte subset and NK cells in the peripheral blood                                          Flow cytometry             In this study, the levels of T-lymphocyte subset and NK cells in the peripheral blood of serofast patients, and healthy controls were compared.

Abbreviation: HCC=hospital-based case-control study; ELISA=enzyme linked immunosorbent assay/

2 cities include Zhangjiakou, and Guangzhou.

In two studies ([@B11], [@B39]), serological cure was defined as either negative nontreponemal antibody test results or a ≥4-fold (2 dilution) decrease in titer after treatment. In remaining studies, serological cure was defined as negative nontreponemal antibodies test results after treatment. For all included studies, serofast status was defined as either no change in titer or a ≤2-fold (1 dilution) titer decrease or increase from baseline, and the titer range at the diagnosis of serofast status was from 1:1 to 1:8. All included studies scored at least six stars according to NOS score system ([Table 2](#T2){ref-type="table"}), so they were considered of low-risk of bias.

###### 

Star template of cohort and case-control studies based on NOS assessment

  **NO**   **Selection**   **Case-control star template**   **Bias assessment**   **Reference number**   **Selection**   **Cohort star template**   **Bias assessment**                         
  -------- --------------- -------------------------------- --------------------- ---------------------- --------------- -------------------------- --------------------- ---- ----- ---------- ----------
  **31**   ☆☆☆             ☆                                ☆☆☆                   ☆☆☆☆☆☆☆                Low risk        **17**                     ☆☆☆                   ☆☆   ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **32**   ☆☆☆             ☆                                ☆☆☆                   ☆☆☆☆☆☆☆                Low risk        **18**                     ☆☆☆                   ☆☆   ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **33**   ☆☆              ☆                                ☆☆☆                   ☆☆☆☆☆☆                 Low risk        **25**                     ☆☆                    ☆    ☆☆☆   ☆☆☆☆☆☆     Low risk
  **34**   ☆☆☆             ☆                                ☆☆☆                   ☆☆☆☆☆☆☆                Low risk        **26**                     ☆☆                    ☆☆   ☆☆☆   ☆☆☆☆☆☆☆    Low risk
  **35**   ☆☆☆☆            ☆☆                               ☆☆☆                   ☆☆☆☆☆☆☆☆☆              Low risk        **27**                     ☆☆☆                   ☆☆   ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **36**   ☆☆              ☆                                ☆☆☆                   ☆☆☆☆☆☆                 Low risk        **28**                     ☆☆                    ☆    ☆☆☆   ☆☆☆☆☆☆     Low risk
  **37**   ☆☆☆☆            ☆                                ☆☆☆                   ☆☆☆☆☆☆☆☆               Low risk        **29**                     ☆☆☆☆                  ☆    ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **38**   ☆☆              ☆                                ☆☆☆                   ☆☆☆☆☆☆                 Low risk        **30**                     ☆☆☆                   ☆☆   ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **39**   ☆☆☆☆            ☆☆                               ☆☆☆                   ☆☆☆☆☆☆☆☆☆              Low risk        **14**                     ☆☆☆                   ☆☆   ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **40**   ☆☆☆             ☆                                ☆☆                    ☆☆☆☆☆☆                 Low risk        **11**                     ☆☆                    ☆    ☆☆☆   ☆☆☆☆☆☆     Low risk
  **41**   ☆☆☆             ☆☆                               ☆☆☆                   ☆☆☆☆☆☆☆☆               Low risk        **10**                     ☆☆☆                   ☆☆   ☆☆☆   ☆☆☆☆☆☆☆☆   Low risk
  **42**   ☆☆☆             ☆☆                               ☆☆☆                   ☆☆☆☆☆☆☆☆               Low risk                                                                               
  **43**   ☆☆☆☆            ☆                                ☆☆☆                   ☆☆☆☆☆☆☆☆               Low risk                                                                               
  **44**   ☆☆☆☆            ☆☆                               ☆☆☆                   ☆☆☆☆☆☆☆☆☆              Low risk                                                                               
  **45**   ☆☆☆☆            ☆☆                               ☆☆☆                   ☆☆☆☆☆☆☆☆☆              Low risk                                                                               
  **46**   ☆☆☆☆            ☆                                ☆☆☆                   ☆☆☆☆☆☆☆☆               Low risk                                                                               

Clinical characteristics of patients with syphilis associated with serofast
---------------------------------------------------------------------------

Trend test showed syphilitic patients with an older age were prone to be serofast after treatment (*P*~**trend**~=0.001). Female patients(sRR=1.50, 95%CI:1.34 to 1.68), latent syphilis (sRR~latent\ vs\ primary~=3.17, 95%CI: 2.66 to 3.77; sRR~latent\ vs\ secondary~=2.00, 95%CI: 1.48 to 2.69), and using non-penicillin treatment(sRR=2.99, 95%CI: 2.45 to 3.67) also increased the risk of serofast, but high baseline titers(\>1:32) of nontreponemal antibodies(sRR=0.63, 95%CI: 0.54 to 0.75) decreased the risk of serofast ([Table 3](#T3){ref-type="table"}). There was no evidence of heterogeneity except for stage of syphilis (all *P* values ≤0.0003; I^2^=71 to 84%). One study (29) showed the TP repeat gene subtype i increased the risk of serofast, when it was compared with sub-type d (RR=4.67, 95%CI: 1.31 to 16.69) and sub-type e (RR=5.00, 95%CI: 0.33 to 75.11), respectively. In one study(14), TP-IgM antibody between serofast patients and syphilitic patients whose serology turned negative after treatment(i.e., serological cure) was detected by fluorescent treponemal antibody absorption(FTA-Abs) and TPPA, and the results showed positive FTA-Abs-TP-IgM(RR=3.27, 95%CI: 2.89 to 3.69) and TPPA-TP-IgM(RR=3.26, 95%CI: 2.89 to 3.68) test increased the risk of serofast, which implied the serofast was associated with occult TP infection.

###### 

Meta-analysis of association between clinical features of patients with syphilis an serofast status

  **Clinical features**                                              **Number of studies**   **Participants**                                                                                  **Heterogeneity**               
  ------------------------------------------------------------------ ----------------------- ------------------ ----------------------- ------------------------------------------------------ ------------------- ----------- -----
    \>=40 *vs* \<=24                                                 3                       963                RR (M-H, FEM, 95% CI)   2.53(1.53,4.19) ^[\*](#TFN5){ref-type="table-fn"}^     4.03                0.57        0%
    \>=40 *vs* 25--39                                                3                       1606               RR (M-H, FEM, 95% CI)   1.99(1.32,3.01) ^[\*](#TFN5){ref-type="table-fn"}^     3.29                0.73        0%
  gender(female *vs* male)                                           7                       3251               RR (M-H, FEM, 95% CI)   1.50(1.34,1.68) ^[\*](#TFN5){ref-type="table-fn"}^     3.38                0.76        0%
  initial titers of non-treponema antibodies (\>1:32 *vs* \<=1:32)   4                       2552               RR (M-H, FEM, 95% CI)   0.63(0.54,0.75) ^[\*](#TFN5){ref-type="table-fn"}^     0.67                0.71        0%
  Stage of syphilis                                                                                                                                                                                                            
    Latent *vs* primary                                              11                      3103               RR (M-H, FEM, 95% CI)   3.17(2.66,3.77) ^[\*](#TFN5){ref-type="table-fn"}^     15.64               0.11        36%
    Latent *vs* secondary                                            10                      3747               RR (M-H, REM, 95% CI)   2.00(1.48,2.69) ^[\*](#TFN5){ref-type="table-fn"}^     55.51               \<0.00001   84%
    Secondary *vs* primary                                           10                      3009               RR (M-H, REM, 95% CI)   1.71 (1.14,2.57) ^[\*](#TFN5){ref-type="table-fn"}^    30.93               0.0003      71%
  Treatment(non-penicillin *vs* penicillin)                          3                       669                RR (M-H, FEM, 95% CI)   2.99(2.45,3.67) ^[\*](#TFN5){ref-type="table-fn"}^     0.72                0.70        0%
  Subtypes of TP repeat gene                                                                                                                                                                                                   
    Subtype i *vs* subtype d                                         1                       36                 RR (M-H, FEM, 95% CI)   4.67 (1.31,16.69) ^[\*](#TFN5){ref-type="table-fn"}^   ---                 ---         ---
    Subtype i *vs* subtype e                                         1                       12                 RR (M-H, FEM, 95% CI)   5.00 (0.33,75.11)                                      ---                 ---         ---
  TP IgM antibody                                                                                                                                                                                                              
    FTA-Abs(positive *vs* negative)                                  1                       1208               RR (M-H, FEM, 95% CI)   3.27(2.89,3.69) ^[\*](#TFN5){ref-type="table-fn"}^     ---                 ---         ---
    TPPA(positive *vs* negative)                                     1                       1208               RR (M-H, FEM, 95% CI)   3.26(2.89,3.68) ^[\*](#TFN5){ref-type="table-fn"}^     ---                 ---         ---

Abbreviation:TP=treponema pallidum; FTA-Abs=fluorescent treponemal antibody absorption; TPPA= treponema pallidum particle agglutination

Statistically significant (P\<0.05)

T-lymphocyte subset and NK cells in the peripheral blood associated with serofast
---------------------------------------------------------------------------------

Present study showed that the serofast was associated with the levels of T-lymphocyte subset in the peripheral blood ([Table 4](#T4){ref-type="table"}). Compared with healthy group, the proportions of CD3(+)(SMD=−0.52, 95%CI: −0.71 to −0.34), CD4(+)(SMD=−0.67, 95%CI: −1.11 to −0.23), Th1 cells(SMD=−1.26, 95%CI: −2.00 to −0.52) and Th1/Th2(SMD=−1.52, 95%CI: −2.29 to −0.76) among serofast patients were decreased, but CD8(+)(SMD=0.58, 95%CI: 0.41 to 0.76), CD4(+)CD25(+) regulatory T cells(SMD=1.92, 95%CI: 1.57 to 2.26), and Th2 cells (SMD=0.91, 95%CI: 0.20 to 1.63) were increased. When compared with serological cure group, the CD4 (+) (SMD=−0.70, 95%CI: −1.26 to −0.14) among serofast patients was also decreased, but CD8 (+) (SMD=0.82, 95%CI: 0.09 to 1.56) and CD4 (+) CD25 (+) regulatory T cells (SMD=2.12, 95%CI: 1.82 to 2.42) were increased. When serological cure group was compared with healthy group, there were no significant difference for the levels of CD3 (SMD=−0.09, 95%CI: −0.38 to 0.20), CD4 (+)(SMD=−0.04, 95%CI: −0.33 to 0.24) and CD8(+) (SMD=−0.18, 95%CI: −0.66 to 0.30). Substantial heterogeneity was observed (all *P* values ≤ 0.006; I^2^=57 to 94%).

###### 

Meta-analysis of association between T-lymphocyte subset and NK cells in the peripheral blood and serofast status

  **T-lymphocyte subset and NK cells**   **Number of studies**   **Participants**   **Statistical methods**   **SMD(95%CI)**                                            **Heterogeneity**               
  -------------------------------------- ----------------------- ------------------ ------------------------- --------------------------------------------------------- ------------------- ----------- -----
  Serofast group *vs* healthy group      8                       512                SMD (IV, REM, 95% CI)     −0.52(−0.71,−0.34) ^[\*](#TFN6){ref-type="table-fn"}^     50.08               \<0.00001   86%
  Serofast group *vs* serological cure   4                       332                SMD (IV, REM, 95% CI)     −0.58 (−1.21, 0.06)                                       22.03               \<0.00001   86%
  Serological cure *vs* healthy group    2                       184                SMD (IV, FEM, 95% CI)     −0.09 (−0.38, 0.20)                                       0.17                0.68        0
  CD4(+)                                                                                                                                                                                                
  Serofast group *vs* healthy group      9                       555                SMD(IV, REM, 95% CI)      −0.67 (−1.11, −0.23) ^[\*](#TFN6){ref-type="table-fn"}^   46.09               \<0.00001   83%
  Serofast group *vs* serological cure   4                       332                SMD (IV, REM, 95% CI)     −0.70 (−1.26, −0.14) ^[\*](#TFN6){ref-type="table-fn"}^   16.93               0.006       57%
  Serological cure *vs* healthy group    2                       184                SMD (IV, FEM, 95% CI)     −0.04 (−0.33, 0.24)                                       0.14                0.71        0
  CD8(+)                                                                                                                                                                                                
  Serofast group *vs* healthy group      9                       555                SMD(IV, FEM, 95% CI)      0.58(0.41, 0.76) ^[\*](#TFN6){ref-type="table-fn"}^       12.31               0.14        35%
  Serofast group *vs* serological cure   4                       332                SMD (IV, REM, 95% CI)     0.82 (0.09, 1.56) ^[\*](#TFN6){ref-type="table-fn"}^      28.09               \<0.00001   89%
  Serological cure *vs* healthy group    2                       184                SMD(IV, REM, 95% CI)      −0.18 (−0.66, 0.30)                                       2.43                0.12        59%
  CD4(+)/CD8(+)                                                                                                                                                                                         
  Serofast group *vs* healthy group      4                       199                SMD (IV, REM, 95% CI)     −0.71 (−1.53, 0.10)                                       20.35               0.0001      85%
  Serofast group *vs* serological cure   1                       43                 SMD(IV, FEM, 95% CI)      0.33(−0.28,0.93)                                          ---                 ---         ---
  Serological cure *vs* healthy group    1                       40                 SMD(IV, FEM, 95% CI)      −1.89(−2.65,−1.13) ^[\*](#TFN6){ref-type="table-fn"}^     ---                 ---         ---
  CD4(+)CD25(+) regulatory T cells                                                                                                                                                                      
    Serofast group *vs* healthy group    2                       206                SMD (IV, FEM, 95% CI)     1.92 (1.57, 2.26) ^[\*](#TFN6){ref-type="table-fn"}^      0.12                0.73        0%
  Serofast group *vs* serological cure   1                       267                SMD (IV, FEM, 95% CI)     2.12(1.82,2.42) ^[\*](#TFN6){ref-type="table-fn"}^        ---                 ---         ---
  NK cell                                                                                                                                                                                               
  Serofast group *vs* healthy group      7                       372                SMD (IV, REM, 95% CI)     −0.85 (−1.80, 0.10)                                       97.40               \<0.00001   94%
  Serofast group *vs* serological cure   2                       93                 SMD (IV, FEM, 95% CI)     −0.13 (−0.54, 0.29)                                       0                   1           0
  Serological cure *vs* healthy group    1                       60                 SMD (IV, FEM, 95% CI)     0.48(−0.04,0.99)                                          ---                 ---         ---
  Th1 cell                                                                                                                                                                                              
  Serofast group *vs* healthy group      1                       43                 SMD (IV, FEM, 95% CI)     −1.26(−2.00,−0.52) ^[\*](#TFN6){ref-type="table-fn"}^     ---                 ---         ---
  Th2 cell                                                                                                                                                                                              
  Serofast group *vs* healthy group      1                       43                 SMD (IV, FEM, 95% CI)     0.91(0.20,1.63) ^[\*](#TFN6){ref-type="table-fn"}^        ---                 ---         ---
  Th1/Th2                                                                                                                                                                                               
  Serofast group *vs* healthy group      1                       43                 SMD (IV, FEM, 95% CI)     −1.52(−2.29,−0.76) ^[\*](#TFN6){ref-type="table-fn"}^     ---                 ---         ---

*Statistically significant (P\<0.05)*

Interleukin and interferon in the serum associated with serofast
----------------------------------------------------------------

Finding from our study demonstrated that the serofast was associated with the levels of interleukin in the serum ([Table 5](#T5){ref-type="table"}). Compared with healthy group, the levels of IL-12 (SMD=−1.56 95%CI: −1.99 to −1.13), IL-2(SMD=−1.06, 95%CI: −1.66 to −0.45), IL-6(SMD= −1.09, 95%CI: −1.42 to −0.75), and IFN-r(SMD=−1.29, 95%CI: −2.31 to −0.26) among serofast patients was decreased, but IL-10(SMD=1.68, 95%CI: 0.75 to 2.60) and IL-4(SMD=0.75, 95%CI: 0.19 to 1.32) were increased. When serofast patients were compared with serological cure group, the levels of IL-2(SMD=−1.03, 95%CI: −1.70 to −0.37) and IL-6(SMD=−1.00, 95%CI: −1.26 to −0.74) was also declined, but IL-10(SMD=2.23, 95%CI: 0.25 to 4.21) was elevated. For the levels of IL-10(SMD=0.11, 95%CI: −0.13 to 0.36), IL-2(SMD=−0.07, 95%CI: −0.63 to 0.50), IL-17(SMD=−0.01, 95%CI: −0.37 to 0.34), IL-23(SMD=−0.02, 95%CI: −0.37 to 0.33), IL-6(SMD=0.19, 95%CI: −0.11 to 0.50), and IFN-r(SMD=0.14, 95%CI: −0.14 to 0.41), there were no significantly statistical difference between serological cure group and healthy group. Substantial heterogeneity was found (all *P* values ≤ 0.006; I^2^=87 to 97%).

###### 

Meta-analysis of association between interleukin and interferon in the serum and serofast status

  **interleukin and interferon IL-10**   **Number of studies**   **Participants**   **Statistical methods**   **SMD(95%CI)**                                            **Heterogeneity**               
  -------------------------------------- ----------------------- ------------------ ------------------------- --------------------------------------------------------- ------------------- ----------- -----
  Serofast group *vs* healthy group      5                       375                SMD(IV, REM, 95% CI)      1.68(0.75, 2.60) ^[\*](#TFN7){ref-type="table-fn"}^       50.53               \<0.00001   92%
  Serofast group *vs* serological cure   3                       347                SMD(IV, REM, 95% CI)      2.23 (0.25, 4.21) ^[\*](#TFN7){ref-type="table-fn"}^      67.12               \<0.00001   97%
  Serological cure *vs* healthy group    3                       303                SMD(IV, FEM, 95% CI)      0.11(−013, 0.36)                                          1.55                0.46        0
  IL-17                                                                                                                                                                                                 
  Serofast group *vs* healthy group      2                       159                SMD (IV, FEM, 95% CI)     −0.15 (−0.46, 0.17)                                       1.72                0.19        42%
  IL-12                                                                                                                                                                                                 
  Serofast group *vs* healthy group      2                       115                SMD (IV, FEM, 95% CI)     −1.56(−1.99, −1.13) ^[\*](#TFN7){ref-type="table-fn"}^    1.63                0.20        39%
  IL-2                                                                                                                                                                                                  
  Serofast group *vs* healthy group      2                       104                SMD (IV, FEM, 95% CI)     −1.06 (−1.66, −0.45) ^[\*](#TFN7){ref-type="table-fn"}^   0.60                0.44        0
  Serofast group *vs* serological cure   1                       40                 SMD (IV, FEM, 95% CI)     −1.03 (−1.70, −0.37) ^[\*](#TFN7){ref-type="table-fn"}^   ---                 ---         ---
  Serological cure *vs* healthy group    1                       50                 SMD (IV, FEM, 95% CI)     −0.07 (−0.63, 0.50)                                       ---                 ---         ---
  IL-17                                                                                                                                                                                                 
  Serofast group *vs* serological cure   1                       121                SMD (IV, FEM, 95% CI)     −0.02 (−0.38, 0.33)                                       ---                 ---         ---
  Serological cure *vs* healthy group    1                       124                SMD (IV, FEM, 95% CI)     −0.01 (−0.37, 0.34)                                       ---                 ---         ---
  IL-23                                                                                                                                                                                                 
  Serofast group *vs* healthy group      1                       123                SMD (IV, FEM, 95% CI)     0.14 (−0.21, 0.50)                                        ---                 ---         ---
  Serofast group *vs* serological cure   1                       121                SMD (IV, FEM, 95% CI)     −0.05 (−0.41, 0.30)                                       ---                 ---         ---
  Serological cure *vs* healthy group    1                       124                SMD (IV, FEM, 95% CI)     −0.02 (−0.37, 0.33)                                       ---                 ---         ---
  IL-6                                                                                                                                                                                                  
  Serofast group *vs* healthy group      1                       170                SMD (IV, FEM, 95% CI)     −1.09(−1.42,−0.75) ^[\*](#TFN7){ref-type="table-fn"}^     ---                 ---         ---
  Serofast group *vs* serological cure   1                       267                SMD (IV, FEM, 95% CI)     −1.00(−1.26,−0.74) ^[\*](#TFN7){ref-type="table-fn"}^     ---                 ---         ---
  Serological cure *vs* healthy group    1                       213                SMD (IV, FEM, 95% CI)     0.19(−0.11,0.50)                                          ---                 ---         ---
  IL-4                                                                                                                                                                                                  
  Serofast group *vs* healthy group      1                       54                 SMD (IV, FEM, 95% CI)     0.75(0.19,1.32) ^[\*](#TFN7){ref-type="table-fn"}^        ---                 ---         ---
  IFN-r                                                                                                                                                                                                 
  Serofast group *vs* healthy group      2                       210                SMD (IV,REM, 95% CI)      −1.29 (−2.31, −0.26) ^[\*](#TFN7){ref-type="table-fn"}^   7.41                0.006       87%
  Serofast group *vs* serological cure   2                       307                SMD (IV, REM, 95% CI)     −1.44 (−3.11, 0.23)                                       22.36               \<0.00001   96%
  Serological cure *vs* healthy group    2                       253                SMD (IV, FEM, 95% CI)     0.14 (−0.14, 0.41)                                        2.0                 0.16        50%

Statistically significant (P\<0.05)

### Publication bias

For gender(*Begg's test: Z=0.19, P=1; Egger's test: t=0.31, P=0.77; Macaskill's test: t=0.22,P=0.84*), latent syphilis *vs* primary syphilis(*Begg's test: Z=0.72,P=0.47; Egger's test: t=1.02,P=0.34; Macaskill's test: t=0.32,P=0.76*), latent syphilis vs secondary syphilis (*Begg's test: Z=0.31,P=0.76; Egger's test: t=1.44,P=0.12;Macaskill's test: t=1.02,P=0.21*), secondary syphilis vs primary syphilis(*Begg's test:Z=0.31,P=0.75;Egger's test: t=0.59, P=0.57;Macaskill's test: t=1.47, P=0.19*), CD3(+)(*Begg's test:Z=1.20,P=0.22;Egger's test:t=1.54,P=0.14;Macaskill's test:t=1.63,P=0.12*), CD4(+)(*Begg's test:Z=0.75,P=0.45; Egger's test:t=0.60,P=0.58; Macaskill's test:t=0.05,P=0.96*), CD8(+) (*Begg's test: Z=0,P=1; Egger's test:t=0.48,P=0.65; Macaskill's test:t=0.46,P=0.67*), and NK cells(*Begg's test: Z=0.75,P=0.45; Egger's test: t=0.59,P=0.57; Macaskill's test: t=1.02,P=0.21*), Egger's test, Begg's test, and Macaskill' test also indicated little evidence of publication bias(*all P\>0.1*).

Sensitivity analysis
--------------------

Sensitivity analyses were conducted to explore potential sources of heterogeneity in the association between serofast and potential risk factors and to examine the influence of various exclusion criteria on the overall risk estimate. In our study, sensitivity analysis was performed only for these factors including ≥6 studies such as gender, stage of syphilis, CD3 (+) (only for the comparison between serofast group and healthy group), CD4 (+)(only for the comparison between serofast group and healthy group), CD8 (+)(only for the comparison between serofast group and healthy group) and NK cells(only for the comparison between serofast group and healthy group). Exclusion of two studies ([@B11], [@B39]) in which serological cure was defined as either negative nontreponemal antibodies test or a ≥4-fold (2 dilution) decrease in titer after treatment, but in remaining studies, serological cure was defined as negative nontreponemal antibodies test after treatment and one study ([@B11]) in which the length from first treatment to diagnosis of serofast was more than 6 months but less than one year yielded similar results. Further exclusion of any single study did not materially alter the overall estimates.

Publication bias
----------------

Considering limited eligible studies for some potential predictors associated with serofast, we only aimed to these factors including ≥6 studies when we assessed publication bias. With regard to these factors, the Begg's funnel plot did not show any substantial asymmetry. In addition, Egger's test, Begg's test, and Macaskill' test also indicated little evidence of publication bias (all *P* \> 0.1).

Discussion
==========

The present study represents, to our knowledge, the first systematic evaluation to assess potential predictors that differentiate HIV-negative individuals from those without serological response by using a systematic review and meta-analysis. Our study including a large proportion of Chinese patients with syphilis (6682 HIV-negative participants infected with Syphilis) with sufficient statistical power aimed at addressing long-term clinical dilemma regarding the mechanism of serofast after treatment. Our findings may serve to guide clinicians regarding the identification of patients who may become serofast after therapy without clear evidence of treatment failure, and provide direct information for conducting targeted interventions in every community in the future, which will help to develop the optimal management program of serofast patients.

Presently, it is still not consistent for definition of the serofast ([@B8]--[@B10], [@B16]). Most Chinese experts think, it is reasonable that the length between first therapy and diagnosis of serofast is 12 months and 24 months for early syphilis(i.e., primary syphilis, secondary syphilis, and early latent syphilis) and late syphilis(infection time \> 2 years), respectively([@B47]). Some studies also indicated if patients' titers after treatment stay at some level (1:1 to 1:8) or have no change more than 3 months after treatment, it should be considered as serofast ([@B47]). In the present study, the shortest length from first treatment to diagnosis of serofast was more than 6 months, and the length in 92.3% of eligible studies was ≥ one year. For all of the studies, the titer range at the diagnosis of serofast was from 1:1 to 1:8.

Finding from our study showed that the serofast was positively associated with older age, female, latent syphilis as well as non-penicillin treatment, but negatively associated with higher baseline titers. Previous studies from other countries confirmed our results ([@B9], [@B48], [@B49]). Using non-penicillin, such as erythromycin and azithromycin, increased the risk of serofast, which implies that penicillin remains preferred drug of choice for treatment of syphilis. However, Sena AC ([@B9]) using data from a large, prospective, controlled trial showed the advantage that using benzathine penicillin to prevent serofast did not exist, when compared with azithromycin. It's worth noting that one study ([@B29]) hinted that the serofast was also positively associated with subtype i of TP repeat gene. However, in this study, the sample size is small. So the association between serofast and subtypes of TP repeat gene need further research. Previous studies ([@B50], [@B51]) also demonstrated that TP repeat gene family has strong variability, which allows TP to evade the body's immune destruction and leads to chronic infection of syphilis. In addition, one study also suggested that the serofast was positively associated with TP occult infection ([@B15]).

It seems that solely relying on clinical characteristics does not fully explain the mechanism of serofast. For example, previous studies([@B9]) confirmed the relationship between the stage of infection and the baseline titer was evident in predicting treatment response, because participants with primary syphilis had a higher proportion of serological cure, whereas 43--58% of patients with secondary or early latent syphilis and baseline titers ≤1:32 were serofast at 6 months after treatment. Recently, investigators attempted to distinguish the cellular response in syphilitic patients after treatment by analyzing the levels of T-lymphocyte subset and NK cells in the peripheral blood, and Interleukin and interferon in the serum associated with serofast ([@B27], [@B31]--[@B46]). From the perspective of the body immune response, our study implies that the serofast was mainly associated with CD4(+) and CD8(+) cells levels in the peripheral blood, and IL-2, IL-6 and IL-10 levels in the serum, and specific performance: the levels of CD4(+), IL-2, and IL-6 are decreased, but the levels of CD8 and IL-10 are increased. Previous studies ([@B50], [@B51]) also suggested that serological response after treatment of syphilis was directly associated with suppression and disorders of body' immune function. However, some studies found no differences in cell types or proportions among individuals with serofast after treatment, compared with normal controls ([@B27]). So further investigations are essential to elucidate the biological basis for the serofast state and to determine whether serofast patients should undergo continued serological monitoring, retreatment, or cerebrospinal fluid examination for TP involvement.

Potential limitations of this study should be considered. Firstly, residual confounders are always of concern in observational studies. Although most included studies adjusted for a wide range of potential confounders for serofast, we still could not exclude the possibility that other unmeasured or inadequately measured factors have confounded the true association. Secondly, there are no widely accepted standards for diagnosis of serofast, and it is unclear for the optimal time point for assessment of serological response. Therefore, the random misclassification of serofast may influence the results. Thirdly, the results have to be viewed with caution because there was significant heterogeneity (I^2^ : from 57 to 97%). Although there was still evidence of heterogeneity, after sensitivity analyses, the result with very few changes was stable and reliable. In addition, the assessment also indicated little evidence of publication bias. So our estimates were considered reasonable. However, these estimates have to be viewed with caution because there was significant heterogeneity. Fourthly, our relatively strict inclusion criteria might have introduced selection bias. Finally, because the results of the current analysis were mainly based on data from Chinese populations, additional research in other populations is warranted to generalize the findings.

Conclusion
==========

The present study represents, to our knowledge, the first systematic evaluation to assess potential predictors that differentiate HIV-negative individuals from those without serological response, using a systematic review and meta-analysis. Although the role of potential bias and evidence of heterogeneity should be carefully evaluated, finding from our study indicated that the older age, female, lower baseline titers, latent course of infection, non-penicillin treatment, TP repeat gene subtype i, TP occult infection as well as the levels of CD4 (+), CD8 (+), IL-2, IL-6 and IL-10 among HIV-negative patients with syphilis should be considered as important predictors of serofast. However, until now the definition and mechanism of serofast has still been not clear, and it is necessary for further research.
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